China National Medicines (600511.SS) – Trading Activity and Market Overview
Trading Performance
- The stock closed flat at 0 % during the 24‑hour period ending 11:52 AM Central Europe time on Thursday 22 October.
- Current trading price is CNY 27.28 on major exchanges.
- Outstanding shares total 735 million.
- Market capitalization stands at CNY 20.3 billion.
- Volume traded in the last 24 hours amounts to CNY 202.9 million.
- Since the close of the previous month, the share price has increased by 5.74 %.
- The 200‑day simple moving average is CNY 27.01.
- 52‑week high: CNY 31.18 (12 November 2025).
- 52‑week low: CNY 25.11 (29 June 2026).
Comparative Stock Activity
| Symbol | Last 24‑hour movement | Current price | Market cap (CNY) | P/E |
|---|---|---|---|---|
| 688301.SS (Iray) | flat 0 % | CNY 72.39 | CNY 24.3 billion | 38.59 |
| 688676.SS (Hainan Jinpan Smart Techno) | flat 0 % | CNY 54.21 | CNY 24.2 billion | 33.84 |
| 600095.SS (Xiangcai) | flat 0 % | CNY 8.11 | CNY 24.2 billion | 27.42 |
| 300747.SZ (Wuhan Raycus Fiber Laser T) | flat 0 % | CNY 42.95 | CNY 24.3 billion | 101.13 |
| 2696.HK (Shanghai Henlius Biotech I‑H) | up 2.68 % | HKD 49.42 | HKD 28.5 billion | 31.4 |
Regulatory and Market Context
- Chinese regulators emphasized alignment between capital markets and the national technology upgrade agenda.
- The discussion highlighted the importance of supportive reforms, inclusive listing, and restructuring mechanisms to accelerate the growth of high‑quality listed firms.
- Analysts noted growing institutional interest in industrial and technology stocks, suggesting that a technology‑sector recovery could be driven by AI‑related demand and dividend‑rich assets.
- The conversation underscored the necessity for long‑term capital that matches the growth timelines of technology companies.
- Overall sentiment is cautiously optimistic regarding the sector’s trajectory, with policymakers and market participants aiming to create a more resilient investment environment for emerging technologies.
Company Overview – China National Medicines China National Medicines Corporation Limited operates as a healthcare provider and service company. Its business activities include the wholesale and retail distribution of chemical material medicines, Western medicine preparations, biochemical medicines, biological products, and traditional Chinese medicines through its subsidiaries. The company also manufactures pharmaceuticals—such as injections, capsules, and tablets—under the CNCM brand name.
